<DOC>
	<DOCNO>NCT02511886</DOCNO>
	<brief_summary>This study determine maximum tolerate dose ( MTD ) arbaclofen placarbil ( AP ) treatment subject Alcohol Use Disorder ( AUD ) . For every two subject receive AP , one subject receive placebo .</brief_summary>
	<brief_title>A Dose-Escalation Study Determine Maximum Tolerated Dose Arbaclofen Placarbil Subjects With Alcohol Use Disorder</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled dose-escalation study determine MTD AP subject AUD . Eighteen ( 18 ) subject randomize receive either AP placebo 2:1 ratio ; ie , 12 subject assign AP 6 assign placebo . Efforts make enroll subject period time one clinical center . The expected maximum duration participation subject 11 week consist 3-week screening period , 30-day residential ( inpatient ) treatment period , 4-week non-residential ( outpatient ) treatment period , end study / early termination clinic visit .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Arbaclofen placarbil</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>1 . 18 65 year age . 2 . Diagnosis AUD confirm MiniInternational Neuropsychiatric Interview . 3 . For require medical detoxification alcohol , subject require complete program detoxification alcohol within 4 day prior screen . 4 . Provide write informed consent prior studyspecific procedure . 5 . Selfreport least 2 heavy drinking day per week 4 week prior screen interview . 6 . Willing abstain drinking time he/she participate study . 7 . Able identify least 1 `` locator '' person assist study staff track subject nonresidential clinic day . 8 . Able read , speak , understand English willing cooperate study procedure . 9 . For female subject , woman childbearing potential must negative pregnancy test prior enrollment must agree use medically acceptable mean contraception screen least 3 month last dose IMP . Male subject female partner childbearing potential must agree use medically acceptable contraception inform consent least 3 month last dose IMP . Male subject must also agree donate sperm study 3 month receive last dose IMP ( Investigational Medicinal Product ) . 1 . Has present symptom history follow disorder : Schizophrenia Schizoaffective Disorder Delusional Disorder Bipolar I Disorder Any mood disorder psychotic feature psychotic disorder Anorexia Nervosa Bulimia Nervosa PostTraumatic Stress Disorder could interfere study Any Personality Disorder could interfere study 2 . Current diagnosis substance use disorder , except nicotine , cannabis ( mild moderate ) , alcohol . 3 . Positive result prohibit medication . 4 . History suicidal ideation within 30 day prior provide write informed consent . 5 . History seizures delirium tremens . 6 . Intention initiate continue additional formal alcoholrelated treatment , include pharmacotherapy , active treatment period . 7 . Have inpatient treatment nonalcohol substance use disorder 12 week prior inform consent . 8 . Total bilirubin &gt; 1.5× upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 3×ULN , aspartate aminotransferase ( AST ) &gt; 3×ULN , serum creatinine &gt; 2×ULN , international normalize ratio ( INR ) &gt; 1.5×ULN , lipase &gt; 3×ULN , amylase &gt; 3×ULN , abnormal pancreatic enzyme value ULN associate clinically significant active pancreatic disorder . 9 . Creatinine clearance &lt; 80 mL/min , calculate accord CockcroftGault equation . 10 . Hemoglobin screen &lt; 11.5 g/dL ( female ) &lt; 12.5 g/dL ( male ) . 11 . Body mass index ( BMI ) &gt; 30 . 12 . Diagnosed unstable medical disorder could increase potential risk study treatment interfere study participation , include follow : 1 . Abnormal cardiac condition , include : Uncontrolled hypertension . History myocardial infarction last year prior history myocardial infarction active complication . Syncopal event within past year . Congestive heart failure . Angina pectoris . QTcF ( QT Fridericiacorrected ) ≥450 msec male ≥470 msec female screen randomization . Clinically significant abnormal find physical exam 12lead ECG . 2 . Diabetes mellitus ( type 1 2 ) fulfilling follow criterion : Glycosylated hemoglobin ( HbA1c ) &gt; 7.5 % screening . Uncontrolled diabetes mellitus . 13 . Have clinically significant abnormal laboratory result 14 . Must donate blood therapeutic phlebotomy ( amount &gt; 300 mL ) receive blood transfusion within 90 day precede enrollment . 15 . Must history surgical procedure involve brain meninges , encephalitis , meningitis , degenerative central nervous system disorder ( eg , Alzheimer 's Parkinson 's Disease ) , epilepsy , mental retardation , disease/procedure/accident/intervention associate significant injury malfunction central nervous system ( CNS ) , history significant head trauma within past 2 year , currently receive anticonvulsant therapy reason . 16 . Must acquire immunodeficiency syndrome ( AIDS ) . 17 . Have active medical condition organ disease may either compromise subject safety interfere safety and/or outcome evaluation IMP . 18 . History presence allergic adverse response ( include rash anaphylaxis ) baclofen ingredient IMP . 19 . Have use baclofen within 30 day prior informed consent . 20 . Taking medication may expect significantly interfere metabolism excretion AP , may associate significant drug interaction AP , may pose significant risk subject 's participation study . 21 . Participation interventional clinical study within 30 day prior informed consent . 22 . Use exclusionary drug ( e.g . antipsychotic , anticonvulsant , benzodiazepine , naltrexone , acamprosate ) . 23 . Site staff subject affiliate , family member , site staff directly involve study . 24 . Be unable comply fully study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Alcohol Abuse</keyword>
	<keyword>Alcohol Addiction</keyword>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Alcohol Induced Disorders</keyword>
	<keyword>Alcoholic Intoxication</keyword>
</DOC>